Lilly Signs a Global Research and Licensing Agreement with Avidity Biosciences to Develop Therapies in Immunology
Shots:
- Avidity to receive $20M upfront- $15M equity investment- $405M as development- regulatory & commercial milestones for each target and royalties on sales. Lilly to get WW rights to develop and commercialize the products to be developed in immunology and other indications
- The companies will develop & commercialize RNA-based therapies with the combination of tissue selectivity of mAb with oligonucleotide-based candidates utilizing Avidity's AOC technology
- Avidity’s antibody oligonucleotide conjugate (AOC) technology combines the cellular and tissue selectivity of mAbs with oligonucleotide-based therapies- modulating RNA in diverse cell types and tissues including muscle- heart- liver- tumors and immune cells
Ref: Eli Lilly | Image: Chemical Industry Digest
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com